Melphalan can rarely cause interstitial pneumonitis and fibrosis. Although it has been reported previously in patients after conventional doses, we report four cases developing diffuse interstitial pneumonitis (DIP) after high-dose melphalan-based therapy. In a 3-year period, four of 57 (7%) 
High-dose melphalan alone or in combination with other chemotherapeutic agents and/or radiation therapy with autologous hematopoietic stem cell transplantation (AHSCT) is increasingly used in the treatment of patients with multiple myeloma and other malignancies. Melphalan, a derivative of mechlorethamine (nitrogen mustard) has a predominantly hematological toxicity profile. 1 The most common extramedullary toxicities are mucositis and gastrointestinal toxicity (eg diarrhea). Pulmonary toxicity due to other alkylators is well known, 2 but there has been a paucity of reports dealing with suspected melphalan pulmonary toxicity. [3] [4] [5] We report our experience in four patients with DIP related to the administration of high-dose melphalan alone or combined with cyclophosphamide followed by AHSCT. Correspondence 
Materials and methods

Patients
Between November 1996 and July 1999, AHSCT was performed in 57 consecutive adult patients with hematologic malignancies. Forty-five patients with multiple myeloma, and 12 patients with non-Hodgkin's lymphoma (NHL) received AHSCT with high-dose melphalan-based preparative regimens. All four patients (one male, three females) were non-smokers. The median age was 61 years (range 51-66). Three patients had multiple myeloma and one had NHL. All patients had an unremarkable pulmonary history except for one patient with NHL who had a history of radiation pneumonitis documented by bronchoscopy 14 weeks prior to transplantation which had responded completely to high-dose corticosteroid therapy. The patient was no longer receiving corticosteroids at the time of her priming chemotherapy and subsequent stem cell transplant. Pulmonary function tests and echocardiography prior to transplantation were all within institutional normal values. All patients had an ECOG performance status 0-1.
Treatment
The chemotherapy preparative regimens used were mel- . Patient characteristics including prior chemotherapy are listed in Table 1 .
Results
Post-transplant courses were unremarkable. All patients achieved successful platelet (Ͼ20 ϫ 10 9 /l) engraftment at a median 20 days (range 13-25 days) and absolute neutrophil counts (Ͼ0.5 ϫ 10 9 /l) at a median 10 days (range 9-11 days). All patients were discharged from the hospital at a median of 21 days (range 18-26 days). Thickened alveolar septae, chronic Improved inflammatory cell infiltrate, PF AEP = atypical epithelial proliferation; PF = pulmonary fibrosis; HYFIG = hydroxyurea, fludarabine, interferon, gallium (institutional protocol); PRF = progressive respiratory failure; M = melphalan; C = cyclophosphamide; A = adriamycin; N = mitoxantrone; P = prednisone; V = vincristine; D = dexamethasone.
Pulmonary complications
Approximately 6 weeks after the AHSCT (median 42 days, range 40-46 days), all four patients developed acute onset of progressive dyspnea, non-productive cough and fever above 39°C necessitating re-admission to the hospital. All four patients had normal white blood counts. All patients were hypoxemic (mean PaO 2 , 65 mmHg; range 55-74 mmHg), and hypocapnic (mean PaCO 2 , 28 mm Hg; range 24-32 mmHg). Chest X-rays and CT scans revealed bilateral diffuse interstitial infiltrates without effusion or cardiomegaly. Repeated blood and sputum cultures for bacterial, fungal and viral studies were negative. Respiratory secretions sent for common respiratory viruses were negative by polymerase chain reaction testing (adenovirus; influenza A and B; parainfluenza 1, 2, 3; respiratory syncytial virus; rhinovirus). Special stains and cultures of all of the specimens for bacteria, mycobacteria, fungi, CMV, and adenovirus were negative. All patients were treated with high-dose corticosteroids consisting of 2 mg/kg/day methylprednisolone. The corticosteroids were initiated after failing broad-spectrum antibiotics in three of the patients; the fourth patient was started on corticosteroids immediately due to the high suspicion of drug-induced interstitial pneumonitis. Three patients required intubation and mechanical ventilation during the course of their illness. The outcomes of the four patients (Table 1) were as follows: Patient 1 died 14 weeks post transplantation from progressive respiratory failure. At autopsy, his lungs showed diffuse pulmonary fibrosis, and atypical epithelial proliferation (AEP). Patient 2 underwent fiberoptic bronchoscopic examination with bronchoalveolar lavage (BAL) and transbronchial biopsy, which revealed moderately thickened alveolar septae with chronic inflammatory cellular infiltrates, and focal pulmonary fibrosis. The patient improved clinically over the first few days, and her chest X ray was back to normal in 10 days. The steroid doses were tapered over 6 weeks. Patient 3 died 20 weeks post transplantation from progressive respiratory failure. Her chest CT scan revealed diffuse ground glass infiltrates. Wedge resection of the lung revealed AEP, alveolar septal thickening, and intra-alveolar fibrin deposition. Patient 4 underwent fiberoptic bronchoscopic examination with BAL and transbronchial biopsy, which revealed alveoli markedly thickened by fibrosis with a sparse chronic inflammatory cell infiltrate. She was started on steroids on the day of admission and had a remarkable clinical response within 72 h. Her chest X-ray cleared within 10 days. Steroids were tapered over the following 6 weeks.
There were no myelomatous or amyloid deposits in any of the biopsy specimens.
Discussion
Alkylating agents including busulfan, cyclophosphamide and nitrosoureas (eg carmustine; BCNU) have been frequently reported to produce serious drug-induced pulmonary toxicity after conventional chemotherapy 2 and following high-dose therapy with hematopoietic stem cell transplant. [6] [7] [8] In contrast, there are only a few reports discussing melphalan-associated lung damage after prolonged exposure to conventional doses of melphalan. [3] [4] [5] None of the previous reports discussed melphalan-associated pulmonary toxicity in the context of high-dose therapy and AHSCT.
The first report of melphalan-induced lung fibrosis was in 1972. 3 On review of 21 autopsies of patients with multiple myeloma, Taetle et al 4 found changes suggestive of druginduced pulmonary fibrotic reactions in five of 10 patients who received chronic conventional-dose melphalan. No such pathologic changes were found in 11 patients with multiple myeloma who had not received this drug. The histological changes seen in chemotherapy-induced lung injury characteristically have been interstitial fibrosis and AEP. 9 Westerfield et al 5 described DIP as early as 40 days after initiating low-dose oral melphalan therapy.
One potentially confounding factor in the development of DIP in our patients was the administration of cyclophosphamide. Cyclophosphamide-induced lung toxicity has two patterns: early and late. 10 The early-onset pneumonitis develops within 1-6 months: the reported cases were treated for prolonged periods with high cumulative doses. The late-onset pattern develops after prolonged latency periods as late as 6 years after discontinuing the drug. The histological findings are nonspecific for cyclophosphamide. Nonetheless, the temporal relationship between cyclophosphamide and subsequent development of DIP raises a strong suspicion that this represents a manifestation of drug toxicity. In our patients the previous and/or concomitant cyclophosphamide treatment may have contributed to the subsequent development of DIP.
In our patients, we observed the development of acute febrile pneumonitis, hypoxemia and acute onset respiratory failure at a median time of 42 days (range 40-46) a time interval which is very similar to that reported with BCNUinduced pneumonitis. [6] [7] [8] Chest CT scans revealed bilateral diffuse interstitial infiltrates without effusion or cardiomegaly. Three of the four patients required intubation and mechanical ventilation: two of the four patients were successfully treated with high-dose corticosteroids. The two patients who were heavily pretreated with alkylators and thoracic wall irradiation in one of them, developed progressive respiratory failure despite high-dose steroids and eventually died. The other two patients previously treated with VAD regimen improved dramatically on high-dose steroids with complete resolution of their pneumonitis.
In summary, four of 57 patients (7%) undergoing MEL or MEL-CY at our institution developed DIP: 2/45 patients (4.4%) who received MEL alone, and 2/12 patients (16.6%) who received MEL-CY. Although reports of pulmonary toxicity resulting from melphalan therapy are rare, the 7% incidence in our series warrants diligent awareness of the potential pulmonary toxicity induced by melphalan especially in the growing setting of MEL 200 or MEL-CY and AHSCT. We recommend that patients who are potential candidates for high-dose therapy and AHSCT should be minimally exposed to alkylators (eg melphalan in case Bone Marrow Transplantation of multiple myeloma) prior to their definitive therapy, in order to minimize subsequent morbidity and mortality.
